A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial. Issue 7 (6th June 2020) - Grosicki, Sebastian; Lech-Maranda, Ewa; Govind Babu, Kanakasetty; Rybka, Justyna; Litvinskaya, Elena; Loscertales, Javier; Kriachok, Iryna; Kłoczko, Janusz; Rekhtman, Grygoriy; Homenda, Wojciech; Blonski, Jerzy; Stefanelli, Tommaso; et al.